Increase in fecal primary bile acids and dysbiosis in patients with diarrhea‐predominant irritable bowel syndrome
- 22 February 2012
- journal article
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 24 (6), 513-e247
- https://doi.org/10.1111/j.1365-2982.2012.01893.x
Abstract
Background Irritable bowel syndrome (IBS) is a multifactorial disease for which a dysbiosis of the gut microbiota has been described. Bile acids (BA) could play a role as they are endogenous laxatives and are metabolized by gut microbiota. We compared fecal BA profiles and microbiota in healthy subjects (HS) and patients with diarrhea-predominant IBS (IBS-D), and we searched for an association with symptoms. Methods Clinical features and stool samples were collected in IBS-D patients and HS. Fecal BA profiles were generated using HPLC coupled to tandem mass spectrometry. The fecal microbiota composition was assessed by q-PCR targeting dominant bacterial groups and species implicated in BA transformation. Key Results Fourteen IBS-D patients and 18 HS were included. The two groups were comparable in terms of age and sex. The percentage of fecal primary BA was significantly higher in IBS-D patients than in HS, and it was significantly correlated with stool consistency and frequency. Fecal counts of all bacteria, lactobacillus, coccoides, leptum and Faecalibacterium prausnitzii were similar. There was a significant increase of Escherichia coli and a significant decrease of leptum and bifidobacterium in IBS-D patients. Conclusions & Inferences We report an increase of primary BA in the feces of IBS-D patients compared to HS, correlated with stool consistency and frequency. A dysbiosis of different bacterial groups was detected, some of them involved in BA transformation. As the gut microbiota is the exclusive pathway to transform primary into secondary BA, this suggests a functional consequence of dysbiosis, leading to lower BA transformation.Keywords
This publication has 35 references indexed in Scilit:
- A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic ConstipationThe American Journal of Gastroenterology, 2011
- Bile acid malabsorption: An under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptomsScandinavian Journal of Gastroenterology, 2011
- Epidemiology of IBSGastroenterology Clinics of North America, 2011
- Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel FunctionClinical Gastroenterology and Hepatology, 2010
- Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferersBMC Gastroenterology, 2009
- Physiological concentrations of bile acids down‐regulate agonist induced secretion in colonic epithelial cellsJournal of Cellular and Molecular Medicine, 2009
- Microbes in Gastrointestinal Health and DiseaseGastroenterology, 2009
- A Rat Model of Chronic Postinflammatory Visceral Pain Induced by Deoxycholic AcidGastroenterology, 2008
- Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patientsProceedings of the National Academy of Sciences of the United States of America, 2008
- Bile Acid Malabsorption in Patients with Chronic Diarrhoea: Clinical Value of SeHCAT TestScandinavian Journal of Gastroenterology, 2003